About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, November 29th, 2017

The QualityStocks
Daily Stock List


Mymetics Corp. (MYMX)

TopPennyStockMovers, Market Intel Reports, and The Dean reported previously on Mymetics Corp. (MYMX), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Mymetics Corp. is a biotechnology company listed on the OTC Markets Group’s OTCQB. The Company is developing next-generation preventative vaccines for infectious diseases. Its vision is to become the market leader in the development of new generation mucosal and virosomes based vaccines. Mymetics has its corporate office in Epalinges, Switzerland.

Mymetics has a Research Lab in the Netherlands. The Company’s core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Currently, Mymetics has a group of vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya, Herpes Simplex Virus, and the RSV vaccine.

The design of the Company’s vaccines is to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which for some pathogens may be critical for the development of an effective prophylactic vaccine. The HIV, malaria, and intra-nasal influenza vaccines have successfully completed Phase 1 clinical trials. The others are in the pre-clinical phase.

Mymetics is concentrating on developing pioneering preventative vaccines utilizing two key scientific approaches. One is Virosomes as an effective adjuvant and a vaccine delivery method. The other is unique antigen design through generating mucosal antibodies.

Through focusing on these two scientific approaches, Mymetics’ strategy is addressing two important needs in developing effective vaccines. One is the ability to build a first line of defense against viruses entering the blood stream through centering on the mucosal layer. The other is the development of a new vaccine delivery platform that doesn’t use live attenuated or killed pathogens, while increasing the immunogenicity and stability of the vaccine.

Mymetics’ subsidiary, Mymetics B.V., has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics' proprietary virosome technology platform in pre-clinical settings.

Mymetics has recently presented new preclinical data. The new data demonstrates that nasal powder, oral capsules, and sublingual tablets developed by MACIVIVA partners, containing Mymetics HIV-1 virosome based vaccine candidate, could induce specific antibody immune response in rodent and mini-pig animal models.

The results are generated under the MACIVIVA project (an EU Horizon 2020 project) that stands for "Manufacturing process for Cold-chain Independent Virosome-based Vaccines." The project began in May of 2015. It has a duration total of 3.5 years.

This project brings together top contract manufacturers and the relevant expertise for spray drying, freeze drying, and analytical techniques from the pharmaceutical industry. This is to develop a scalable manufacturing process to attain thermostable and cold-chain independent virosome based vaccines.

Mymetics Corp. (MYMX), closed Wednesday's trading session at $0.0232, down 10.08%, on 123,500 volume with 7 trades. The average volume for the last 60 days is 723,964 and the stock's 52-week low/high is $0.01/$0.095.

Park Place Energy, Inc. (PKPL)

Zacks, Amigo Bulls, Market Exclusive, Barchart, Marketwired, Proactive Investors, and MarketWatch reported on Park Place Energy, Inc. (PKPL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

An energy company, Park Place Energy, Inc. engages in oil and natural gas exploration and production. It has a number of oil and gas assets in Turkey and Bulgaria. The Company is concentrating on building a portfolio of international exploration and development projects in Turkey and Southeast Europe. Its focus is on recently acquired oil and gas producing assets in Turkey and a coal bed methane exploration license in Bulgaria.

Park Place Energy is headquartered in Dallas, Texas. It also has an office in Ankara, Turkey and a satellite office in Sofia, Bulgaria. The Company lists on the OTC Markets Group’s OTCQB.

In Turkey, the Company’s assets include a 19.6 percent interest in the Cendere oil field, a 37.25 percent interest in the SASB offshore gas field (together which net Park Place roughly 180 bopd.), a 100 percent interest in 42,833 hectares (105,797 acres) of contiguous exploration blocks (Derecik Exploration Licences) encompassing the northern extension of the prolific Iraq/Kurdistan Zagros Basin, and the Vranino 1-11 block, Bulgaria, a prospective coal bed methane property. Park Place Energy plans to drill new wells in 2018.

In Turkey, the South Akcakoca Sub-Basin (SASB) gas field was first discovered in 2004 with a total of 22 wells drilled in the field. There are now 10 wells connected to the existing infrastructure. Moreover, the Cendere oil field is a field discovered in the 1990s. Cendere is a long lived oil field. At present, there are 16 producing wells.

Pertaining to the Vranino project, it is in close proximity to a major gas pipeline in northeast Bulgaria. The area encompassed by the License Agreement was previously widely explored for the potential to mine coal in the deep coal beds found in the Dobrudja Basin. Based upon this previous coal exploration activity, the Company knows these coal beds are a potentially prolific source of natural gas.

Between the 1960’s and the late 1980’s, greater than 220 wells were drilled on the Vranino 1-11 Block and the immediate surrounding area. In addition, one additional well was drilled in 2005. Of the wells, 120 wells are positioned on the Vranino 1-11 Block and intersect targeted gas bearing coal seams at depths of between 1200 meters and 2500 meters.

Last month, Park Place Energy reported Revenues from oil and gas production for the six months ending June 30, 2017 of $ 1,672,639 versus Nil Revenue for the same period during 2016. Its Revenue for the quarter ending June 30, 2017 was $1,046,423. Park Place Energy reported a Net Loss of $1,431,458 for the six months ending June 30, 2017 and a Net Loss of $ 850,104 for the quarter then ended.

Park Place Energy, Inc. (PKPL), closed Wednesday's trading session at $0.0771, up 8.59%, on 23,693 volume with 8 trades. The average volume for the last 60 days is 16,610 and the stock's 52-week low/high is $0.071/$0.62.

Dakota Territory Resource Corp. (DTRC)

Innovative Marketing, OTC Markets Group, and UltimatePennyStock reported previously on Dakota Territory Resource Corp. (DTRC), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Dakota Territory Resource Corp.’s concentration is on the acquisition and responsible exploration and development of high caliber gold properties in the Black Hills of South Dakota. The Company maintains 100 percent ownership of three mineral properties. These include the Blind Gold, City Creek, and Homestake Paleoplacer Properties. All of these are in the heart of the Homestake District.  Dakota Territory Resource has its corporate headquarters in Reno, Nevada.

The Blind Gold Property is the Company’s flagship property. It is a target for Tertiary-aged and Iron-formation gold mineralization.  The Blind Gold Property is roughly four miles northwest and on structural trend with the historic Homestake Gold Mine.  The Homestake Gold Mine produced approximately 40 million ounces of gold through its 125-year production history. It is the largest iron-formation-hosted gold deposit in the world.

Dakota Territory Resource’s intention is to continue its sampling program along trend of the zone of high grade gold mineralization identified by the first pass surface sampling program conducted on its 100 percent owned Blind Gold Property. This program identified a zone of high-grade gold mineralization in the Mississippian-age Pahasapa Limestone on the surface, with a peak gold assay value of 9.44 grams per tonne. Dakota is preparing for drilling in the Homestake Gold District of South Dakota.

The Homestake Paleoplacer Property comprises 13 unpatented lode mining claims. These are situated one-mile north of the Homestake Open Cut. Dakota Territory Resource based the acquisition of its Black Hills property position on greater than 44 years of combined mining and exploration experience in the Homestake District.

The Company’s City Creek Property is a target for Homestake iron-formation gold mineralization. City Creek comprises 21 unpatented lode mining claims. These are positioned one-mile northeast of the Homestake Open Cut and one-mile northwest of the City of Deadwood.

Dakota Territory Resource announced in April 2017 that it entered into agreements with Trucano Novelty, Inc. to acquire a combination of surface and mineral title to 284 acres in the Homestake District of the Northern Black Hills of South Dakota. Dakota presently holds about 3,341 acres in the heart of the district. Moreover, Dakota Territory Resource’s research of historic data identified high grade gold mineralization under the Company’s recently acquired property at Maitland.

Dakota Territory Resource Corp. (DTRC), closed Wednesday's trading session at $0.0341, even for the day, on 5,040 volume with 3 trades. The average volume for the last 60 days is 5,329 and the stock's 52-week low/high is $0.023/$0.10.

Relmada Therapeutics, Inc. (RLMD)

SmallCap Network, Investors Alley, Trade of the Week, Wallstreetbuzz, Investopedia, ProfitableTrading, The Observer, PCG Advisory, Streetwise Reports, Penny Stock Bets, StreetAuthority Financial, Dividend Opportunities, and WallstreetsHotteststocks reported on Relmada Therapeutics, Inc. (RLMD), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Relmada Therapeutics, Inc. is a clinical-stage, specialty pharmaceutical company. It centers on developing novel versions of proven drug products in combination with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. Relmada Therapeutics has a diverse portfolio of lead products at different stages of development. It is developing novel therapies for the treatment of central nervous system (CNS) diseases. The Company is headquartered in New York, New York.

Relmada Therapeutics’ lead products are d-Methadone (REL-1017), its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine - MepiGel (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine - BuTab (REL-1028), its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol.

The Company’s BuTab (REL-1028) is its investigational, oral formulation of buprenorphine, an opioid that is extensively used to treat addiction and chronic pain. The design of BuTab is to be delivered orally and reach safe and effective blood levels of buprenorphine via the gastrointestinal route of administration due to its modified release profile.

In June 2016, Relmada Therapeutics received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia. In July 2016, Relmada announced it was granted a patent from the European Patent Office (EPO) for compositions and methods of use for its extended release oral levorphanol (3-hydroxy-N-methylmorphinan).

Relmada Therapeutics announced in April 2017 that the FDA granted Fast Track designation for d-Methadone (REL-1017 dextromethadone), the Company’s novel N-methyl-D-aspartate (NMDA) receptor antagonist in development for the adjunctive treatment of major depressive disorder.

Relmada plans to advance the development program for REL-1017 to a Phase 2a randomized, double-blind, placebo-controlled study in patients with major depressive disorder. The study will evaluate changes in depressive symptoms and the safety, tolerability, and pharmacokinetics of two dose levels of REL-1017 as rapid acting adjunctive treatment in patients during a seven-day dosing period and 14-day observation period.

In late October, Relmada Therapeutics announced that IP Australia issued a notice of acceptance for patent application number 2013323645 for "D-methadone for the treatment of psychiatric symptoms." The patent application provides extensive coverage for d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist, in Australia as a treatment for symptoms associated with a spectrum of psychological and psychiatric disorders. These include depression, anxiety, fatigue, as well as mood instability.

Mr. Sergio Traversa, Relmada Therapeutics’ Chief Executive Officer, said in October, "This latest milestone provides strong additional IP protection in a strategically and commercially important part of the world for the development of dextromethadone as a rapidly acting depression treatment."

Relmada Therapeutics, Inc. (RLMD), closed Wednesday's trading session at $0.72, down 4.00%, on 30,490 volume with 20 trades. The average volume for the last 60 days is 13,331 and the stock's 52-week low/high is $0.61/$1.40.

Wound Management Technologies, Inc. (WNDM)

Greenbackers, Market News Alerts, Wall Street News Alert, SmallCapVoice, UndiscoveredEquities, FeedBlitz, and Hawk Associates reported earlier on Wound Management Technologies, Inc. (WNDM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Wound Management Technologies, Inc. is an emerging commercial stage company listed on the OTC Markets Group’s OTCQB. Its main products are in the $5B global advanced wound care market. The Company’s chief focus is the distribution of its Wound Care Innovations subsidiary's inventive, patent-protected and Food and Drug Administration (FDA)-cleared collagen product, CellerateRX®. This is for all wound types except 3rd degree burns. Wound Management Technologies is based in Fort Worth, Texas.

Wound Care Innovations, LLC (WCI) is a wholly-owned subsidiary of Wound Management Technologies. WCI has the exclusive worldwide licensing and distribution rights for CellerateRX® advanced wound care collagen products. CellerateRX® is active in all four phases of wound healing.

Furthermore, the Company’s Resorbable Orthopedic Products (ROP) subsidiary owns a multi-faceted bone wax and bone void filler patent. It markets products in the $1.5B biomaterials market. ROP receives royalty income on this patent in addition to the new revenues expected from HemaQuell Resorbable Bone Wax.

HemaQuell is a water soluble material utilized as a tamponade to control bleeding from bone surfaces. The basis of it is on the multi-faceted patent that Wound Management Technologies acquired in 2009. HemaQuell will be delivered in a unique patent-pending applicator. This applicator allows surgeons to directly apply the waxy product on bleeding bones.

The HemaQuell bone hemostasis material is entirely resorbed between two and seven days. It does not delay healing of bone injury. The Company’s Resorbable Orthopedic Products (ROP) subsidiary has received FDA 510(k) clearance for HemaQuell Resorbable Bone Wax.

The CellerateRX® product is safe, non-toxic, as well as easy to use. In addition, it is available in powder (95 percent collagen) and gel (65 percent) forms. These do not require special handling, such as refrigeration.

CellerateRX®'s activated collagen is about 1/100th the size of native collagen. This activated collagen delivers the essential benefits of collagen to a wound right away. CellerateRX® is applied easily by patients by themselves at home.

This past July, Wound Management Technologies announced the publication of the paper "Operative Closure Technique Utilizing Bovine Collagen Fragments in a Prospective Analysis of 102 Consecutive Neurosurgery Patients" by Rob Dickerman, Ashley S. Reynolds NP, and Karl Winters, in JSM Neurosurgery and Spine.

The authors present a prospective study of 102 consecutive cranial or spinal neurosurgery cases in which 1 gram of Vancomycin powder was mixed with 1 gram of Activated Collagen (CellerateRX Surgical Activated Collagen Powder) and subsequently placed within the surgical incision. In the 102 consecutive cases, they did not have a single event of wound dehisce or infection during the 16-week follow-up period.

Wound Management Technologies is in the process of obtaining a Conformité Européene, (European Conformity) Mark (CE Mark) for its HemaQuell™ Resorbable Bone Hemostat.

Wound Management Technologies, Inc. (WNDM), closed Wednesday's trading session at $0.054, down 16.92%, on 249 volume with 2 trades. The average volume for the last 60 days is 46,702 and the stock's 52-week low/high is $0.0354/$0.10.

Nemaura Medical, Inc. (NMRD)

Market Exclusive, OTC Markets, and 4-Traders reported on Nemaura Medical, Inc. (NMRD), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.

Nemaura Medical, Inc. is a medical technology company listed on the OTC Markets Group’s OTCQB. It is developing the wireless sugarBEAT® disposable adhesive skin-patch as a non-invasive, needle-free, pain-free, and affordable continuous glucose monitoring (CGM) system for adjunctive use by diabetics. Nemaura’s patient-friendly technology has the potential to transform health monitoring through providing real-time, tailored feedback on glucose, lactate, and other key body performance metrics. Nemaura Medical has its head office in Loughborough, England

The Company’s patented BEAT™ technology (passing a mild, non-perceptible electric current across the skin) draws a small number of selected molecules, such as glucose, into a patch placed on the skin. These molecules are drawn out of the interstitial fluid. The patch (by way of a sensor) measures the amount of that molecule present, converting it into a meaningful concentration value for clinical diagnosis or preliminary guidance for self-treatment.

The BEAT™ technology will permit remote continuous monitoring of chronic diseases and health conditions. It is to replace traditional invasive methods of diagnosis and healthcare observation procedures.

Nemaura’s sugarBEAT® provides accurate glucose measurement. SugarBEAT® consists of a reusable transmitter containing a daily-disposable adhesive skin-patch.

The SugarBEAT® App can be pre-downloaded on a user’s smart device. There is an optional sugarBEAT® handheld reader (applicable where a user selects not to use their own smart device).

Nemaura Medical announced this past June that the latest version of the sensor component of its sugarBEAT® non-invasive, wireless skin-patch realized a greater than 300 percent improvement in glucose detection. The expectation is that this significant improvement will enhance sugarBEAT® accuracy as expressed through MARD, through enabling diabetics to better detect small fluctuations in glucose levels, and for sugarBEAT® to detect glucose at very low levels.

In August, Nemaura Medical announced it signed a non-binding term sheet with Device Technologies for exclusive rights to market and sell sugarBEAT® in Australia and New Zealand. Device Technologies is a foremost Medical Device distributor. Nemaura Medical’s expectation is to launch in Australia and New Zealand next year.

Recently, Nemaura Medical announced interim clinical trial results for the sugarBEAT® European clinical trial programme. The programme comprises 525 patient days, consisting of 75 patients continuously wearing sugarBEAT® for up to 14 hours per day over 7 consecutive days in a combination of home and clinic settings. The expectation is that these will determine safety, accuracy, precision and utility of sugarBEAT® as an adjunct to finger stick testing. Interim results based on 175 patient days completed as of September 21, 2017 detected no skin irritation or serious adverse events.

For Q2 ended September 30, 2017, Nemaura Medical started European clinical trials for sugarBEAT®. The Company also successfully developed a medical grade sugarBEAT® android app for diabetes management.

Nemaura Medical, Inc. (NMRD), closed Wednesday's trading session at $5.00, even for the day, on 350 volume with 2 trades. The average volume for the last 60 days is 5,247 and the stock's 52-week low/high is $1.40/$9.60.

CTD Holdings, Inc. (CTDH)

Greenbackers, Wall Street Resources, Nebula Stocks, and HotStockChat reported previously on CTD Holdings, Inc. (CTDH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A biotechnology company, CTD Holdings, Inc. is developing cyclodextrin-based products for the treatment of disease. This includes Trappsol® Cyclo™. The Company’s other divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies engaged in the research, pharmaceutical, medical device, cosmetics, and nutrition markets. CTD Holdings is based in Alachua, Florida.

The Company’s Trappsol® Cyclo™ is an orphan drug designated product. It is for the treatment of Niemann-Pick Type C (NPC). This is a rare and frequently fatal genetic disease in young children. The disease also results in major health impairment for affected adults. NPC impacts the brain, lung, liver, spleen, and other organs.

Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. This includes peripheral artery disease, diabetic nephropathy, and acute viral infections.

CTD Holdings’ other divisions operate the world's only cGMP pulse drying facility to produce UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. In addition, they supply cyclodextrins to biotechnology and life science researchers globally from the world's largest catalog of cyclodextrins.

CTD Holdings filed a Clinical Trial Application (CTA) with Italy's drug regulator, the Agenzia Italiana del Farmaco (AIFA) to conduct a Phase I/II clinical trial in Italy of CTD's orphan drug product Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C.

The UK Medicines and Healthcare Products Agency (MHRA) approved the Company’s CTA for its Trappsol® Cyclo™, in the treatment of Niemann-Pick Type C (NPC) disease. The CTA described the Company’s Phase I/II clinical plans to administer Trappsol® Cyclo™ intravenously to patients in the UK as young as two years old and into adulthood. The product has Orphan Drug Designation in the European Union and the United States.

In September of this year, CTD Holdings announced that it enrolled the first patient in its US Phase I clinical trial evaluating the intravenous administration of Trappsol® Cyclo™ in patients with Niemann-Pick Disease Type C (NPC). The first patient was enrolled at UCSF Benioff Children's Hospital Oakland, the single site for this trial, by Dr. Caroline Hastings, pediatric hematologist and oncologist. Dr. Hastings is the Principal Investigator for the US Phase I trial.

This Phase I clinical trial will necessitate 12 patients to be fully enrolled. The trial is a double-blind randomized trial evaluating two doses of Trappsol® Cyclo™, 1500 mg/kg or 2500 mg/kg, in NPC patients 18 years of age and older.

Furthermore, CTD Holdings has started a multi-center international Phase I/II clinical trial in Europe. This clinical trial is evaluating intravenous administration of Trappsol® Cyclo™ in NPC patients.

CTD Holdings, Inc. (CTDH), closed Wednesday's trading session at $0.389, even for the day. The average volume for the last 60 days is 10,578 and the stock's 52-week low/high is $0.25/$0.80.


The QualityStocks
Company Corner


AppSwarm, Inc. (SWRM)

The QualityStocks Daily Newsletter would like to spotlight AppSwarm, Inc. (SWRM). Today, AppSwarm, Inc. closed trading at $0.043, up 377.78%, on 31,918,903 volume with 1,351 trades. The stock’s average daily volume over the past 60 days is 313,006 and its 52-week low/high is $0.002/$0.03.

AppSwarm, Inc. (OTC:SWRM), a technology company specializing in the accelerated development and publishing of mobile apps has completed development plans with SinglePoint (OTC:SING) to conduct a shared roll-out of mobile applications specifically geared to solve issues in the cannabis space using the Blockchain technology and Bitcoin payment options. The applications and tech will be modelled and marketed under SinglePoint’s SingleSeed subsidiary (SingleSeed.com), while AppSwarm (www.app-swarm.com) will provide the necessary technical support and application development. The venture calls for a 50/50 revenue share on all products to be deployed.

AppSwarm, Inc. (SWRM) is a technology development and incubation acceleration company that partners up with developers through joint ventures, royalty agreements, marketing partnerships, and outright purchase agreements. Focusing on the ever-growing mobile applications market, the company provides all the resources needed for engagement, retention, virality and monetization.

The global games market generated approximately $100 billion in revenues in 2016, but large global game companies have made it extremely difficult for smaller developers to achieve success in the marketplace. As a result, many great ideas aren't monetized. AppSwarm solves this problem by providing the funding and critical business expertise needed to successfully launch and market new applications.

Business applications is another area of focus for the company. Targeting small to medium sized businesses, AppSwarm will be developing and acquiring mobile application tools and platforms that increase productivity and security via data encryption, cloud storage, content management and delivery, digital payments, automation, and customer loyalty marketing solutions. Recent acquisitions made so far represent only a small example of future planned initiatives to develop and market tools for the business community.

Regardless of the target market, AppSwarm can help developers accelerate the success of their app through funding, technology and marketing expertise, as well as a unique eco system that accelerates user acquisition. The company is able to assist at any state of development with completion of concept, market analysis, business and financial management, direct sales and marketing, social game development to ensure correct product application and expedient deployment with cost efficiency.

Ron Brewer, CEO of the company, has accumulated extensive leadership in the technology sector and brings valuable knowledge gained as a Director of Southbridge Advisory Group for nearly 20 years. Ron's C-level experience includes merger & acquisition and post-acquisition turnaround in both the private and small-cap public sector. John Rabbit, director of finance, is a seasoned business veteran that has worked with Fortune 500 firms and served in CEO, COO and CFO positions for firms ranking from $5 million to $300 million in annual revenues. John was directly involved in numerous acquisitions and served in executive capacities for several multinational subsidiaries.

With a well-suited management team, multiple synergistic revenue streams, and diversified growth strategy, AppSwarm is well positioned in a steadily growing industry with countless opportunities for capitalization. Disclaimer

AppSwarm, Inc. Blog

AppSwarm, Inc. News:

AppSwarm and SinglePoint Finalize Plans for Cannabis and Bitcoin Focused Applications and Technology

AppSwarm, Inc. (SWRM) and USA Real Estate Holding Company (USTC) Sign LOI to Launch Bitcoin Mobile Wallet

AppSwarm and SinglePoint Sign LOI to Conduct a Shared Roll-Out of Mobile Applications Specifically Geared to the Cannabis Industry

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.109, up 24.00%, on 83,892,348 volume with 5,684 trades. The stock’s average daily volume over the past 60 days is 5,688,947, and its 52-week low/high is $0.01/$0.415.

AppSwarm, Inc. (OTC:SWRM), a technology company specializing in the accelerated development and publishing of mobile apps has completed  development plans with SinglePoint (OTC:SING) to conduct a shared roll-out of mobile applications specifically geared to solve issues in the cannabis space using the Blockchain technology and Bitcoin payment options. The applications and tech will be modelled and marketed under SinglePoint’s SingleSeed subsidiary (SingleSeed.com), while AppSwarm (www.app-swarm.com) will provide the necessary technical support and application development. The venture calls for a 50/50 revenue share on all products to be deployed.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

AppSwarm and SinglePoint Finalize Plans for Cannabis and Bitcoin Focused Applications and Technology

CannabisNewsWire Announces Publication on the Price of Bitcoin and Several Investment Options in Cryptocurrency

SinglePoint (SING) Launches Proprietary Bitcoin Exchange to Solve Payment Processing Issues in High-Risk Markets

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $0.765, up 1.66%, on 175,380 volume with 92 trades. The stock’s average daily volume over the past 60 days is 118,696 and its 52-week low/high is $0.2185/$2.119.

MGX Minerals Inc. (MGXMF) is pleased to report that engineering partner PurLucid Treatment Solutions Inc. has developed high temperature filtration for the purification of geothermal brines and associated extraction of metals and minerals including lithium.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Announces Ultra High Temperature Filtration for Extraction of Lithium from Geothermal Brine

MGX Minerals Announces New Discoveries and Completion of 50 Hole Drill Program at Case Lake Lithium, Ontario; 20 Hole Follow-up Drill Program Set For January 2018

MGX Minerals Announces Case Lake Lithium Project Drilling Nears Completion

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.80, off by 11.11%, on 275,471 volume with 205 trades. The stock’s average daily volume over the past 60 days is 227,981 and its 52-week low/high is $0.1999/$1.01.

The cannabis market is exploding globally as well as domestically, and Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has pioneered an enabling technology that enhances the body’s absorption of cannabinoids—an advancement from which many cannabis-related companies can profit.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Technology Offers a Sweet Escape for Cannabis Users without Smoking or Sweeteners

Lexaria Bioscience Files Innovative New Patent Application

NetworkNewsWire Announces Publication on the Wide-Ranging Potential of Patented Technology for Improved Bioabsorption


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $1.1477, off by 10.91%, on 931,795 volume with 673 trades. The stock’s average daily volume over the past 60 days is 387,665 and its 52-week low/high is $0.6171/$1.42.

ABcann Global Corporation (OTCQB:ABCCF) today announces the release of its financial results for the three and nine months ended September 30, 2017. Copies of the interim filings, including the Management’s Discussion and Analysis for the period, are available under the Company’s SEDAR profile at http://www.sedar.com/.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidl

y-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:
ABcann Global Announces Financial Results and Provides Operational Update

NetworkNewsWire Announces Publication on Investment Capital Pouring into Canada's Legal Cannabis Market

Outsized Demand in Canada’s Cannabis Market Triggers Upswing in Smart Money Flowing North

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.632, off by 7.06%, on 1,009,130 volume with 468 trades. The stock’s average daily volume over the past 60 days is 57,832 and its 52-week low/high is $0.171/$0.7401.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), announces the appointment of Mr. Robert “Rob” Dawson to its advisory board. Mr. Dawson is a highly-regarded expert in marketing and innovation with a wealth of experience in business leadership, go-to-market strategy, branding and technology.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas Pharma Appoints of BC's "Top 40 Under 40" Robert Dawson – a Highly Regarded Marketing & Innovation Expert to Its Advisory Board

US Patent Office Acknowledges Provisional Patent Application for Use of Specific Cannabis Strain to Enhance Opioid Analgesia Filed by Veritas’ Research Arm Cannevert

Cannevert Scientists to Present Their First Peer-Reviewed Research at December’s Prestigious British Pharmacological Society Meeting in London, UK

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.058, up 5.45%, on 900 volume with 2 trades. The stock’s average daily volume over the past 60 days is 20,634, and its 52-week low/high is $0.007/$0.59.

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

Sully Project - E3 Target Drilling Underway

Kootenay Zinc Corp.: Sully Project Exploration Update

NetworkNewsWire Releases Exclusive Audio Interview with Kootenay Zinc Corp. (KTNNF)


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(SWRM) +377.78%


Damn Good Penny Picks
(WCTXF) +51.18%


(PYDGF) +42.57%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251